JSPRW
Jasper Therapeutics, Inc.
Set alert
- YTD
- -98.94%
- 1 year
- -98.94%
- Open
- 0.08
- Prev close
- 0.0013
- Mkt cap
- 3.25K
- Vol
- 863.07K
- Avg vol
- 0
- EPS
- -3.84
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0001
- High
- 0.0039
- Forward P/E
- 0.00
- Beta
- 2.20
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.04
- EPS (TTM)
- -3.84
- Beta
- 2.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -36.91M
- Total cash
- 92.50M
- Total debt
- 2.07M
- Return on equity
- -71.46%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- jaspertherapeutics.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on JSPRW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cowen and Company, LLC | 44.12% | 2,206,248 | 507.44K | Sep 29, 2024 |
| Walleye Capital LLC | 11.92% | 596,014 | 137.08K | Sep 29, 2024 |
| Tenor Capital Management Co., L.p. | 5.00% | 250,000 | 57.50K | Sep 29, 2024 |
| Zazove Associates LLC | 1.31% | 65,456 | 15.05K | Sep 29, 2024 |
| Walleye Trading LLC | 0.28% | 14,095 | 3.24K | Sep 29, 2024 |